338 related articles for article (PubMed ID: 19754386)
1. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis.
Bäck M
Curr Pharm Des; 2009; 15(27):3116-32. PubMed ID: 19754386
[TBL] [Abstract][Full Text] [Related]
2. Leukotriene pathway genetics and pharmacogenetics in allergy.
Duroudier NP; Tulah AS; Sayers I
Allergy; 2009 Jun; 64(6):823-39. PubMed ID: 19416143
[TBL] [Abstract][Full Text] [Related]
3. Human bronchial fibroblasts express the 5-lipoxygenase pathway.
James AJ; Penrose JF; Cazaly AM; Holgate ST; Sampson AP
Respir Res; 2006 Jul; 7(1):102. PubMed ID: 16872537
[TBL] [Abstract][Full Text] [Related]
4. The 5-lipoxygenase pathway regulates vasculogenesis in differentiating mouse embryonic stem cells.
Finkensieper A; Kieser S; Bekhite MM; Richter M; Mueller JP; Graebner R; Figulla HR; Sauer H; Wartenberg M
Cardiovasc Res; 2010 Apr; 86(1):37-44. PubMed ID: 19965960
[TBL] [Abstract][Full Text] [Related]
5. Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy.
Sveinbjörnsson B; Rasmuson A; Baryawno N; Wan M; Pettersen I; Ponthan F; Orrego A; Haeggström JZ; Johnsen JI; Kogner P
FASEB J; 2008 Oct; 22(10):3525-36. PubMed ID: 18591367
[TBL] [Abstract][Full Text] [Related]
6. Novel leukotriene biosynthesis inhibitors (2012-2016) as anti-inflammatory agents.
Werz O; Gerstmeier J; Garscha U
Expert Opin Ther Pat; 2017 May; 27(5):607-620. PubMed ID: 28005436
[TBL] [Abstract][Full Text] [Related]
7. Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome.
Gautier-Veyret E; Bäck M; Arnaud C; Belaïdi E; Tamisier R; Lévy P; Arnol N; Perrin M; Pépin JL; Stanke-Labesque F
Pharmacol Res; 2018 Aug; 134():311-319. PubMed ID: 29920371
[TBL] [Abstract][Full Text] [Related]
8. Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors.
Lee E; Lindo T; Jackson N; Meng-Choong L; Reynolds P; Hill A; Haswell M; Jackson S; Kilfeather S
Am J Respir Crit Care Med; 1999 Dec; 160(6):2079-85. PubMed ID: 10588632
[TBL] [Abstract][Full Text] [Related]
9. Summary: the enzymes, accessory proteins, and receptors of leukotriene metabolism and their inhibition and antagonism.
Dennis EA; Krell RD
Adv Prostaglandin Thromboxane Leukot Res; 1994; 22():63-7. PubMed ID: 7771350
[No Abstract] [Full Text] [Related]
10. Antileukotriene treatment in children with asthma--new patents.
Stelmach I; Grzelewski T
Recent Pat Inflamm Allergy Drug Discov; 2008 Nov; 2(3):202-11. PubMed ID: 19076010
[TBL] [Abstract][Full Text] [Related]
11. Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis.
Figueroa DJ; Borish L; Baramki D; Philip G; Austin CP; Evans JF
Clin Exp Allergy; 2003 Oct; 33(10):1380-8. PubMed ID: 14519144
[TBL] [Abstract][Full Text] [Related]
12. FLAP inhibitors for the treatment of inflammatory diseases.
Sampson AP
Curr Opin Investig Drugs; 2009 Nov; 10(11):1163-72. PubMed ID: 19876784
[TBL] [Abstract][Full Text] [Related]
13. Leukotriene synthases and the receptors induced by peripheral nerve injury in the spinal cord contribute to the generation of neuropathic pain.
Okubo M; Yamanaka H; Kobayashi K; Noguchi K
Glia; 2010 Apr; 58(5):599-610. PubMed ID: 19908283
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase.
Gupta N; Nicholson DW; Ford-Hutchinson AW
Can J Physiol Pharmacol; 1997; 75(10-11):1212-9. PubMed ID: 9431445
[TBL] [Abstract][Full Text] [Related]
15. 5-Lipoxygenase: a target for antiinflammatory drugs revisited.
Steinhilber D
Curr Med Chem; 1999 Jan; 6(1):71-85. PubMed ID: 9873115
[TBL] [Abstract][Full Text] [Related]
16. Expression of leukotriene biosynthetic enzymes in tonsillar tissue of children with obstructive sleep apnea: a prospective nonrandomized study.
Tsaoussoglou M; Hatzinikolaou S; Baltatzis GE; Lianou L; Maragozidis P; Balatsos NA; Chrousos G; Kaditis AG
JAMA Otolaryngol Head Neck Surg; 2014 Oct; 140(10):944-50. PubMed ID: 25211287
[TBL] [Abstract][Full Text] [Related]
17. The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field.
Whatling C; McPheat W; Herslöf M
Expert Opin Investig Drugs; 2007 Dec; 16(12):1879-93. PubMed ID: 18041998
[TBL] [Abstract][Full Text] [Related]
18. Enzymes and receptors in the leukotriene cascade.
Haeggström JZ; Wetterholm A
Cell Mol Life Sci; 2002 May; 59(5):742-53. PubMed ID: 12088275
[TBL] [Abstract][Full Text] [Related]
19. 5-lipoxygenase and FLAP.
Peters-Golden M; Brock TG
Prostaglandins Leukot Essent Fatty Acids; 2003; 69(2-3):99-109. PubMed ID: 12895592
[TBL] [Abstract][Full Text] [Related]
20. Leukotriene biosynthetic enzymes as therapeutic targets.
Haeggström JZ
J Clin Invest; 2018 Jul; 128(7):2680-2690. PubMed ID: 30108195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
